Validation of PCR method for mycoplasma detection in the Yellow Fever-vaccine quality control
Keywords:
mycoplasma, PCR, vaccine, yellow fever
Abstract
Among the vaccines produced by Bio-Manguinhos, a major centre for manufacturing the immunobiological products in Latin America, stands out the yellow fever (YF) vaccine. To guarantee the excellence and safety of the YF vaccine, the quality control tests has to be performed throughout its production. The World Health Organization (WHO) demands the producers to guarantee the absence of Mycoplasma orale, M. pneumoniae, M. gallisepticum and M. synoviae in the biological products. Mycoplasma is a fastidious microorganism, requiring about 35 days for attaining the conclusive culturing test. In this study PCR methods were selected for amplifying 16SrRNA gene fragments for detecting mycoplasma in the intermediate products of YF vaccine. This standardized methodology was specific and sensitive to detect the low concentrations of mycoplasma in spiked intermediary vaccine products; and the absence of unspecific amplification was also demonstrated. The detection rates ranged from 3.1 to 12.5 colony forming units and showed 100 % of sensitivity and specificity in the tested samples. The PCR protocol for detecting mycoplasmal DNA in YF vaccine was validated by analysing 286 samples. Bio-Manguinhos produces annually 10,000,000 YF vaccine doses, and this method has been successfully employed, complementing the traditional approach in the mycoplasma detection since 2008.
Published
2016-10-25
How to Cite
Lawson-Ferreira, R., Santos, J. P. S., Parmera, D., Guimarães, R. C., Coelho, J. B. de C., Frota, S. C., Mattoso, J. M. V., Oliveira, C. C. P. de, Hokama, D. A., Filippis, I. de, Nascimento, E. R. do, & Caride, E. C. (2016). Validation of PCR method for mycoplasma detection in the Yellow Fever-vaccine quality control. Revista Do Instituto Adolfo Lutz, 75, 01-13. Retrieved from https://periodicoshomolog.saude.sp.gov.br/index.php/RIAL/article/view/33519
Issue
Section
ORIGINAL ARTICLE